McArthur and Associates is very pleased to welcome John Van Drie’s specialised experience applying in silico tools to structure-based drug discovery. Following graduate work at the California Institute of Technology, a fellowship at the Université Libre de Bruxelles, Brussels, Belgium. John has worked closely within the biopharmaceutical industry, academic groups and venture capitalists.
He has worked with Novartis both in Basel, Switzerland and was the director of the CADD group at Novartis in Cambridge MA. As a senior scientist in drug discovery, John has contributed to the oxazolidinone antibiotic research team at Vertex Pharmaceuticals in Boston MA as well at Pharmacia and Upjohn in Kalamazoo, MI. John was a member of the research team that discovered Abbott’s ritonavir, the first marketed HIV protease inhibitor for AIDS infections. He was a founding member of BioCad in Sunnyvale CA where he contributed to the development of the novel drug design software, Catalyst, which has since been marketed by Accelrys.
His diverse industrial experience has enabled him to discover and co-invent novel molecular intellectual property and to help academic groups looking to turn their intellectual property into a form suitable for forming the basis of a startup. Further, John has worked closely with investors looking to invest in novel computational technology as well as novel drug discovery technology. His joining McArthur and Associates significantly expands our range of consulting services that we can offer to the biopharmaceutical industry and related investors.